Regulus Therapeutics

RGLSNASDAQ
$1.77
-0.26-12.59%
Last update: 10:30 AM
15 minutes delayed
Regulus Therapeutics (RGLS) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$28.00
Lowest Price Target1
$2.00
Consensus Price Target1
$9.50

Regulus Therapeutics (NASDAQ:RGLS) Stock, Analyst Ratings, Price Targets, Predictions

Regulus Therapeutics Inc has a consensus price target of $9.5, established from looking at the 20 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, HC Wainwright & Co., and Jones Trading on June 25, 2024, June 25, 2024, and May 31, 2024. With an average price target of $15.33 between Canaccord Genuity, HC Wainwright & Co., and Jones Trading, there's an implied 766.29% upside for Regulus Therapeutics Inc from these 3 analyst ratings.

Analyst Trends and Forecast
1
1
Mar
0
0
0
0
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.5
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Canaccord Genuity
HC Wainwright & Co.
Jones Trading
Leerink Partners
Wells Fargo

1calculated from analyst ratings

Analyst Ratings for Regulus Therapeutics

Buy NowGet Alert
06/25/2024Buy Now1481.92%Canaccord Genuity
Whitney Ijem
$11 → $28MaintainsBuyGet Alert
06/25/2024Buy Now464.97%HC Wainwright & Co.
Raghuram Selvaraju
$9 → $10MaintainsBuyGet Alert
05/31/2024Buy Now351.98%Jones Trading
Catherine Novack
 → $8Initiates → BuyGet Alert
05/10/2024Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
05/06/2024Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
03/25/2024Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
03/19/2024Buy Now521.47%Canaccord Genuity
Whitney Ijem
$12 → $11MaintainsBuyGet Alert
03/18/2024Buy Now238.98%Leerink Partners
Joseph Schwartz
 → $6Initiates → OutperformGet Alert
03/18/2024Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
03/13/2024Buy Now69.49%Wells Fargo
Jim Birchenough
$2 → $3MaintainsEqual-WeightGet Alert
09/21/2023Buy Now577.97%Canaccord Genuity
Whitney Ijem
$9 → $12MaintainsBuyGet Alert
09/21/2023Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
09/19/2023Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
06/28/2023Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
06/21/2023Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
05/15/2023Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
 → $9ReiteratesBuy → BuyGet Alert
04/21/2023Buy Now408.47%HC Wainwright & Co.
Raghuram Selvaraju
$20 → $9MaintainsBuyGet Alert
11/08/2022Buy Now408.47%Canaccord Genuity
Whitney Ijem
 → $9Initiates → BuyGet Alert
09/02/2021Buy Now12.99%Cantor Fitzgerald
Brian Cheng
—Initiates → OverweightGet Alert

FAQ

Q

What is the target price for Regulus Therapeutics (RGLS) stock?

A

The latest price target for Regulus Therapeutics (NASDAQ:RGLS) was reported by Canaccord Genuity on June 25, 2024. The analyst firm set a price target for $28.00 expecting RGLS to rise to within 12 months (a possible 1481.92% upside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Regulus Therapeutics (RGLS)?

A

The latest analyst rating for Regulus Therapeutics (NASDAQ:RGLS) was provided by Canaccord Genuity, and Regulus Therapeutics maintained their buy rating.

Q

When was the last upgrade for Regulus Therapeutics (RGLS)?

A

There is no last upgrade for Regulus Therapeutics

Q

When was the last downgrade for Regulus Therapeutics (RGLS)?

A

There is no last downgrade for Regulus Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Regulus Therapeutics (RGLS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regulus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regulus Therapeutics was filed on June 25, 2024 so you should expect the next rating to be made available sometime around June 25, 2025.

Q

Is the Analyst Rating Regulus Therapeutics (RGLS) correct?

A

While ratings are subjective and will change, the latest Regulus Therapeutics (RGLS) rating was a maintained with a price target of $11.00 to $28.00. The current price Regulus Therapeutics (RGLS) is trading at is $1.77, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch